Rigel Pharmaceuticals

Yahoo Finance • 10 days ago

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Explosive Growth, Fits Navellier's 'Little Book' Strategy

Rigel Pharmaceuticals Inc (NASDAQ:RIGL [https://www.chartmill.com/stock/quote/RIGL]) has become an interesting option for growth investors using the screening method from Louis Navellier's "The Little Book That Makes You Rich." This invest... Full story

Yahoo Finance • 17 days ago

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines High Growth Momentum with Strong Technical Setup

For investors aiming to merge fundamental momentum with technical accuracy, a multi-layered screening method can produce strong opportunities. By selecting for stocks with a High Growth Momentum Rating above 4, a Technical Rating above 7,... Full story

Yahoo Finance • 23 days ago

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock

In the changing environment of equity investing, the search for growth at a reasonable price is a fundamental strategy for many investors. This method, often called "affordable growth" or GARP (Growth At Reasonable Price), tries to find co... Full story

Yahoo Finance • 27 days ago

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A Deep Value Stock with Strong Fundamentals

In value investing, finding stocks that trade below their intrinsic value while having good basic fundamentals is a key strategy. This method, based on the ideas of Benjamin Graham and later made famous by Warren Buffett, aims to find chan... Full story

Yahoo Finance • 29 days ago

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • last month

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Growth Stock on Navellier's Screening Model

Rigel Pharmaceuticals Inc (NASDAQ:RIGL [https://www.chartmill.com/stock/quote/RIGL]) has become an interesting candidate for growth investors using the screening method from Louis Navellier's "The Little Book That Makes You Rich." This inv... Full story

Yahoo Finance • last month

Target Stock Market Leaders Rising In Heavy Volume With This Powerful Screen

Leading stocks catching the attention of institutional investors are always worth monitoring during market uptrends and downtrends. Continue Reading View Comments... Full story

Yahoo Finance • last month

H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the top most undervalued biotech stocks to buy now. On August 6, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with a... Full story

Yahoo Finance • last month

Unusual volume stocks in Monday's session

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT AUUD [https://www.chartmill.com/stock/quote/AUUD/profile]... Full story

Yahoo Finance • 2 months ago

Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances

Earnings Call Insights: Rigel Pharmaceuticals (RIGL) Q2 2025 MANAGEMENT VIEW * Raul R. Rodriguez, President and CEO, stated that "this was a really great quarter for Rigel" and highlighted net product sales of more than $58 million, ma... Full story

Yahoo Finance • 2 months ago

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoin... Full story

Yahoo Finance • 2 months ago

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Aligns Perfectly with Louis Navellier’s Growth Investing Strategy

Louis Navellier’s _The Little Book That Makes You Rich_ presents a growth investing strategy centered on finding stocks with solid earnings momentum, rising sales, and better profitability. The method uses eight main rules, each meant to i... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 3, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and set... Full story

Yahoo Finance • 3 months ago

Rigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potential

Rigel Pharmaceuticals , Inc. (NASDAQ:RIGL), a biotechnology company focused on developing innovative therapies for hematologic disorders, cancer, and rare immune diseases, has been making significant strides in its clinical pipeline and co... Full story

Yahoo Finance • 2 years ago

Rigel to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies 2023 London Hea... Full story

Yahoo Finance • 2 years ago

Investors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 55% over the last five years

We think intelligent long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an example, the Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) share price dropped 55% in the last half decade. We certainly fee... Full story

Yahoo Finance • 2 years ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compens... Full story

Yahoo Finance • 3 years ago

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by rec... Full story

Yahoo Finance • 3 years ago

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 /PRNews... Full story

Yahoo Finance • 3 years ago

Increasing losses over year doesn't faze investors as stock surges 10% this past week

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders will doubtless be very grateful to see the share price up 97% in the last month. But that doesn't change the fact that the returns over the last year have been disappointing. During th... Full story